Literature DB >> 10435629

Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity.

P Legoix1, O Bluteau, J Bayer, C Perret, C Balabaud, J Belghiti, D Franco, G Thomas, P Laurent-Puig, J Zucman-Rossi.   

Abstract

To determine the frequency of Wnt/Wingless beta catenin pathway alteration in human hepatocellular carcinoma, a beta catenin and APC gene mutation screening was performed in a series of 119 tumors. An activating beta catenin mutation in exon 3 was found in 18% of the cases. Among tumors lacking beta catenin mutation, no APC mutation has been evidenced in a subset of 30 cases tested. The correlation between beta catenin mutation status and chromosome segment deletions was studied on a set of 48 hyperploid tumors. Chromosome 1p, 4q and 16p deletions were significantly associated with the absence of beta catenin mutation (P<0.05). Furthermore the Fractional Allelic Loss was significantly smaller in the beta catenin mutated tumors than in the non-mutated tumors (0.12 versus 022). Taken together, these results suggest, the existence of two carcinogenesis mechanisms. The first mechanism implies a beta catenin activating mutation associated with a low rate of loss of heterozygosity. The second mechanism, operating in a context of chromosomal instability, would involve tumor suppressor genes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10435629     DOI: 10.1038/sj.onc.1202800

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  36 in total

1.  Negative feedback loop in T cell activation through IkappaB kinase-induced phosphorylation and degradation of Bcl10.

Authors:  Camille Lobry; Tatiana Lopez; Alain Israël; Robert Weil
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-09       Impact factor: 11.205

2.  The beta-catenin/TCF4 pathway modifies alternative splicing through modulation of SRp20 expression.

Authors:  Vânia Gonçalves; Paulo Matos; Peter Jordan
Journal:  RNA       Date:  2008-10-24       Impact factor: 4.942

3.  Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling.

Authors:  Emily M Cousins; Dennis Goldfarb; Feng Yan; Jose Roques; David Darr; Gary L Johnson; Michael B Major
Journal:  Mol Cancer Res       Date:  2017-11-13       Impact factor: 5.852

4.  Accelerated liver regeneration and hepatocarcinogenesis in mice overexpressing serine-45 mutant beta-catenin.

Authors:  Kari N Nejak-Bowen; Michael D Thompson; Sucha Singh; William C Bowen; Mohd Jamal Dar; Jaspal Khillan; Chunsun Dai; Satdarshan P S Monga
Journal:  Hepatology       Date:  2010-05       Impact factor: 17.425

5.  Epidermal growth factor receptor: a novel target of the Wnt/beta-catenin pathway in liver.

Authors:  Xinping Tan; Udayan Apte; Amanda Micsenyi; Emorphia Kotsagrelos; Jian-Hua Luo; Sarangarajan Ranganathan; Dulabh K Monga; Aaron Bell; George K Michalopoulos; Satdarshan P S Monga
Journal:  Gastroenterology       Date:  2005-07       Impact factor: 22.682

Review 6.  β-Catenin Signaling and Roles in Liver Homeostasis, Injury, and Tumorigenesis.

Authors:  Satdarshan Pal Monga
Journal:  Gastroenterology       Date:  2015-03-05       Impact factor: 22.682

Review 7.  Wnt signaling in liver cancer.

Authors:  Yutaka Takigawa; Anthony M C Brown
Journal:  Curr Drug Targets       Date:  2008-11       Impact factor: 3.465

Review 8.  DNA markers in molecular diagnostics for hepatocellular carcinoma.

Authors:  Ying-Hsiu Su; Selena Y Lin; Wei Song; Surbhi Jain
Journal:  Expert Rev Mol Diagn       Date:  2014-08-07       Impact factor: 5.225

Review 9.  Genetically modified animal models recapitulating molecular events altered in human hepatocarcinogenesis.

Authors:  Aránzazu Sánchez; Isabel Fabregat
Journal:  Clin Transl Oncol       Date:  2009-04       Impact factor: 3.405

10.  Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma.

Authors:  Bin Yang; Mingzhou Guo; James G Herman; Douglas P Clark
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.